Back de Leiva, A, Brugus, E, de Leiva-Prez, A (Nov 2011) 'El descubrimiento de la insulina: continan las controversias despus de noventa aos', Endocrinologa, Diabetes y Nutricin , 58, 449-56
There's a healthier way to lose weight with weight-loss medication
By targeting appetite reduction and energy expenditure with dual or triple agonists, it may be possible to pharmacologically mimic the effects seen with bariatric surgery to produce 3040% body weight reduction, diabetes remission and CV benefits (83, 84)
A Semaglutide GLP-1 weight loss program typically lasts several months to over a year, depending on a persons goals, how their body responds, and medical supervision
In summary, the combination of GLP-1RAs with other GI peptide receptor agonists appears to amplify the effects of GLP-1R activation, and these combinations are currently being investigated in preclinical and clinical studies, not only for the treatment of T2D but also for the treatment of other metabolic disorders